Outcomes of Primary Vs. Staged Repair in 4628 Neonates with Symptomatic Tetralogy of Fallot: A Systematic Review and Meta-analysis
- PMID: 40659877
- DOI: 10.1007/s00246-025-03949-8
Outcomes of Primary Vs. Staged Repair in 4628 Neonates with Symptomatic Tetralogy of Fallot: A Systematic Review and Meta-analysis
Abstract
There are two strategies to treat neonates with symptomatic tetralogy of Fallot (TOF), primary repair (PR) and staged repair (SR). There is still a debate on the best surgical strategy. We aim to compare PR and SR regarding mortality and comorbidities. We executed a systematic search on PubMed, Embase, Scopus, Web of Science (WOS), and Cochrane Central till January 10, 2025. We included studies with neonates with symptomatic TOF who received an intervention within the first 30 days of life, either with SR or PR. The primary outcomes were in-hospital, 30-day, and 2-year mortality rates. We used Review Manager to calculate the risk ratio (RR) and its 95% confidence interval (CI) for categorical variables and the mean difference (MD) and its 95% CI for continuous outcomes. A P-value less than 0.05 was considered significant. The I-squared test was used to assess heterogeneity. The RRs of mortality at 30 days and 2 years were comparable between both approaches (RR = 0.53; [95% CI = 0.22-1.27], P = 0.15) and (RR = 1.22; [95% CI = 0.0.99-1.51], P = 0.07) respectively. While the length of hospital stay (MD = 18.47 days; [95% CI = 10.87-26.08], P < 0.00001), length of intensive care unit stay (MD = 4.18 days; [95% CI = 3.12-5.23], P < 0.00001), and cardiopulmonary bypass time (MD = 46,47 day; [95% CI = 37.71-55.24], P < 0.00001), all were longer with SR. PR and SR strategies are equivalent regarding short- and long-term mortality in neonates with symptomatic TOF.
Keywords: Primary repair; Staged repair; Tetralogy of Fallot.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval and consent: This type of research requires neither ethical approval nor patients’ informed consent.
References
-
- Duro RP, Moura C, Leite-Moreira A (2010) Anatomophysiologic basis of tetralogy of Fallot and its clinical implications. Rev Port Cardiol 29(4):591–630 - PubMed
-
- Diaz-Frias J, Guillaume M (2022) Tetralogy of Fallot. In: StatPearls, StatPearls Publishing, Treasure Island
-
- Ossa Galvis MM, Bhakta RT, Tarmahomed A, Mendez MD (2022) Cyanotic heart disease. In: StatPearls, StatPearls Publishing, Treasure Island
-
- Parker SE et al (2010) Updated national birth prevalence estimates for selected birth defects in the United States, 2004–2006. Birth Defects Res Part A 88(12):1008–1016. https://doi.org/10.1002/bdra.20735 - DOI
-
- Ali N (2015) Tetralogy of Fallot. JAAPA 28(6):65–66. https://doi.org/10.1097/01.JAA.0000462058.86000.b6 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
